• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚洲癌症防治共同体——亚洲国家癌症中心联盟。

An Asian Body to Tackle Cancers in Asia - The Asian National Cancer Centers Alliance.

机构信息

National Cancer Center, Japan, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

National Cancer Centre Singapore, 11, Hospital Crescent, Singapore.

出版信息

Asian Pac J Cancer Prev. 2020 May 1;21(5):1207-1212. doi: 10.31557/APJCP.2020.21.5.1207.

DOI:10.31557/APJCP.2020.21.5.1207
PMID:32458623
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7541889/
Abstract

The socioeconomic burden of cancer is growing rapidly in the Asian region, with a concentrated burden on low- and middle- income countries. The residents of this region, representing almost 60% of the global population, demonstrate an eclectic and complex nature, with huge disparities in ethnicity, sociocultural practices among others. The Asian National Cancer Centers Alliance (ANCCA) was established in 2005 by heads of several national cancer centers (NCCs) in the region to address common issues and concerns among Asian countries. During the first 13 years of ANCCA's existence, the participating NCCs' senior managers paved the way toward collaboration through transparent sharing of key facts and activities. Concrete achievements of the Alliance include the Asia Tobacco-Free Declaration, the establishment of the ANCCA Constitution in 2014 as well as the creation of an official website more recently. In November 2019, the most active ANCCA members (China, India, Indonesia, Japan, Korea, Mongolia, Singapore, Thailand, and Vietnam) strengthened the bonds of the entity with the clear aim to halt the increase in cancer and mortality rates in Asian countries by 2030. New opportunities including accelerated cooperation between members as well as collaboration with external and multidisciplinary stakeholders at local, regional and international levels are an essential step to most effectively tackle cancers in Asia.

摘要

亚洲地区癌症的社会经济负担迅速增加,中低收入国家负担沉重。该地区的居民占全球人口的近 60%,他们的种族、社会文化习俗等差异巨大,具有折衷和复杂的特点。亚洲国家癌症中心联盟(ANCCA)于 2005 年由该地区几个国家癌症中心的负责人成立,旨在解决亚洲国家共同关心的问题。在 ANCCA 存在的前 13 年,参与的国家癌症中心的高级管理人员通过透明地分享关键事实和活动,为合作铺平了道路。该联盟的具体成就是发布了《亚洲烟草控制宣言》,2014 年制定了《ANCCA 章程》,最近还创建了一个官方网站。2019 年 11 月,最活跃的 ANCCA 成员(中国、印度、印度尼西亚、日本、韩国、蒙古、新加坡、泰国和越南)加强了该实体的联系,明确目标是到 2030 年遏制亚洲国家癌症发病率和死亡率的上升。包括成员之间加速合作以及与地方、区域和国际各级的外部和多学科利益攸关方合作在内的新机会,是在亚洲有效应对癌症的重要一步。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c5/7541889/c6cb8f06b044/APJCP-21-1207-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c5/7541889/3ff062938520/APJCP-21-1207-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c5/7541889/c6cb8f06b044/APJCP-21-1207-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c5/7541889/3ff062938520/APJCP-21-1207-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c5/7541889/c6cb8f06b044/APJCP-21-1207-g002.jpg

相似文献

1
An Asian Body to Tackle Cancers in Asia - The Asian National Cancer Centers Alliance.亚洲癌症防治共同体——亚洲国家癌症中心联盟。
Asian Pac J Cancer Prev. 2020 May 1;21(5):1207-1212. doi: 10.31557/APJCP.2020.21.5.1207.
2
Feasibility of monitoring Global Breast Cancer Initiative Framework key performance indicators in 21 Asian National Cancer Centers Alliance member countries.在21个亚洲国家癌症中心联盟成员国监测全球乳腺癌倡议框架关键绩效指标的可行性
EClinicalMedicine. 2023 Dec 16;67:102365. doi: 10.1016/j.eclinm.2023.102365. eCollection 2024 Jan.
3
Present status of cancer treatment in several Asian countries.几个亚洲国家癌症治疗的现状。
Gan To Kagaku Ryoho. 1992 Jul;19(8 Suppl):1153-9.
4
Mapping recommendations towards an Asian Code Against Cancer (ACAC) as part of the World Code Against Cancer Framework: an Asian National Cancer Centers Alliance (ANCCA) initiative.作为《世界抗癌法典》框架一部分的亚洲抗癌法典(ACAC)映射建议:亚洲国家癌症中心联盟(ANCCA)倡议。
Lancet Reg Health Southeast Asia. 2023 Nov 22;24:100316. doi: 10.1016/j.lansea.2023.100316. eCollection 2024 May.
5
Population policies in Southeast Asia and Australia: the international relevance of domestic affairs.东南亚和澳大利亚的人口政策:国内事务的国际关联
J Aust Popul Assoc. 1984 Spring;1:109-20. doi: 10.1007/BF03029405.
6
State of rare disease management in Southeast Asia.东南亚罕见病管理状况。
Orphanet J Rare Dis. 2016 Aug 2;11(1):107. doi: 10.1186/s13023-016-0460-9.
7
Challenges and outlook for the UICC-Asian Regional Office.国际抗癌联盟亚洲区域办事处面临的挑战与展望
Asian Pac J Cancer Prev. 2013;14(8):4935-7. doi: 10.7314/apjcp.2013.14.8.4935.
8
The Impact of COVID-19 on Cancer Care in the Post Pandemic World: Five Major Lessons Learnt from Challenges and Countermeasures of Major Asian Cancer Centres.后疫情时代 COVID-19 对癌症护理的影响:亚洲主要癌症中心应对挑战和采取的对策中吸取的五大经验教训。
Asian Pac J Cancer Prev. 2021 Mar 1;22(3):681-690. doi: 10.31557/APJCP.2021.22.3.681.
9
Preparing for the Next Pandemic: An Asian National Cancer Centers Alliance (ANCCA) Initiative.为下一次大流行做准备:亚洲国家癌症中心联盟(ANCCA)倡议。
Asian Pac J Cancer Prev. 2021 Sep 1;22(9):2945-2950. doi: 10.31557/APJCP.2021.22.9.2945.
10
A consensus plan for action to improve access to cancer care in the association of Southeast Asian Nations (ASEAN) region.东南亚国家联盟(东盟)地区改善癌症护理可及性的共识行动计划。
Asian Pac J Cancer Prev. 2014;15(19):8521-6. doi: 10.7314/apjcp.2014.15.19.8521.

引用本文的文献

1
Mapping recommendations towards an Asian Code Against Cancer (ACAC) as part of the World Code Against Cancer Framework: an Asian National Cancer Centers Alliance (ANCCA) initiative.作为《世界抗癌法典》框架一部分的亚洲抗癌法典(ACAC)映射建议:亚洲国家癌症中心联盟(ANCCA)倡议。
Lancet Reg Health Southeast Asia. 2023 Nov 22;24:100316. doi: 10.1016/j.lansea.2023.100316. eCollection 2024 May.
2
Changing Colorectal Cancer Trends in Asians: Epidemiology and Risk Factors.亚洲人结直肠癌趋势的变化:流行病学与风险因素
Oncol Rev. 2023 May 22;17:10576. doi: 10.3389/or.2023.10576. eCollection 2023.
3
Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries.

本文引用的文献

1
Rare cancers are not rare in Asia as well: The rare cancer burden in East Asia.亚洲的罕见癌症也不少见:东亚的罕见癌症负担。
Cancer Epidemiol. 2020 Aug;67:101702. doi: 10.1016/j.canep.2020.101702. Epub 2020 Jun 11.
2
Beyond the hype of big data and artificial intelligence: building foundations for knowledge and wisdom.超越大数据和人工智能的炒作:为知识和智慧奠定基础。
BMC Med. 2019 Jul 17;17(1):143. doi: 10.1186/s12916-019-1382-x.
3
Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project.
在四个东南亚国家对晚期非鳞状非小细胞肺癌进行诊断评估和全身治疗。
ESMO Open. 2022 Oct;7(5):100560. doi: 10.1016/j.esmoop.2022.100560. Epub 2022 Aug 18.
4
Preparing for the Next Pandemic: An Asian National Cancer Centers Alliance (ANCCA) Initiative.为下一次大流行做准备:亚洲国家癌症中心联盟(ANCCA)倡议。
Asian Pac J Cancer Prev. 2021 Sep 1;22(9):2945-2950. doi: 10.31557/APJCP.2021.22.9.2945.
5
Economic Distress of Breast Cancer Patients Seeking Treatment at a Tertiary Cancer Center in Mumbai during COVID-19 Pandemic: A Cohort Study.《COVID-19 大流行期间,孟买一家癌症专科医院寻求治疗的乳腺癌患者的经济困境:一项队列研究》。
Asian Pac J Cancer Prev. 2021 Mar 1;22(3):793-800. doi: 10.31557/APJCP.2021.22.3.793.
6
The Impact of COVID-19 on Cancer Care in the Post Pandemic World: Five Major Lessons Learnt from Challenges and Countermeasures of Major Asian Cancer Centres.后疫情时代 COVID-19 对癌症护理的影响:亚洲主要癌症中心应对挑战和采取的对策中吸取的五大经验教训。
Asian Pac J Cancer Prev. 2021 Mar 1;22(3):681-690. doi: 10.31557/APJCP.2021.22.3.681.
我们找到解开罕见癌症治疗发展滞后之谜的关键了吗?:主钥匙项目。
Clin Pharmacol Ther. 2019 Sep;106(3):491-492. doi: 10.1002/cpt.1453. Epub 2019 May 23.
4
"Asian" Phenotype Underestimates the Genetic Diversity of Asia yet Overstates its Impact on Variability in Drug Disposition and Pharmacodynamics.“亚洲人”表型低估了亚洲的遗传多样性,但高估了其对药物处置和药效学变异性的影响。
Clin Pharmacol Ther. 2019 Apr;105(4):802-805. doi: 10.1002/cpt.1329. Epub 2019 Feb 10.
5
Stakeholder involvement in systematic reviews: a scoping review.利益相关者参与系统评价:范围综述。
Syst Rev. 2018 Nov 24;7(1):208. doi: 10.1186/s13643-018-0852-0.
6
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
7
Current state of therapeutic development for rare cancers in Japan, and proposals for improvement.日本罕见癌症治疗开发的现状及改善建议。
Cancer Sci. 2018 May;109(5):1731-1737. doi: 10.1111/cas.13568.
8
UICC-ARO Symposium at the UICC 2016 World Cancer Congress How Can We Mobilize Action to Realize UHC in Asia?国际抗癌联盟(UICC)-德国放射肿瘤学会(ARO)在2016年UICC世界癌症大会上举办的研讨会:我们如何动员各方行动以在亚洲实现全民健康覆盖?
Asian Pac J Cancer Prev. 2017 Nov 26;18(11):2897-2901. doi: 10.22034/APJCP.2017.18.11.2897.
9
Improving access to high-cost cancer drugs in Latin America: Much to be done.改善拉丁美洲高成本癌症药物的可及性:仍有许多工作要做。
Cancer. 2017 Apr 15;123(8):1313-1323. doi: 10.1002/cncr.30549. Epub 2017 Feb 9.
10
Safety of Cancer Therapies: At What Cost?癌症治疗的安全性:代价几何?
Popul Health Manag. 2017 Aug;20(4):318-328. doi: 10.1089/pop.2016.0097. Epub 2017 Jan 23.